NanoString Technologies, Inc. (NSTG)

NanoString Technologies, Inc. develops and sells tools for genomic and proteomic analysis, serving the scientific and clinical research communities. Their nCounter Analysis System and GeoMx DSP system are key platforms for spatial biology and molecular diagnostics.

46/100 AI Score MCap $5.07M Vol 21.43M

Company Overview

CEOR. Bradley Gray
Employees550
HeadquartersSeattle, WA, US
IPO Year2013

NanoString Technologies empowers scientific discovery and clinical insights with its innovative spatial biology and molecular profiling solutions, offering researchers and clinicians advanced tools for genomics and proteomics analysis, driving personalized medicine and improved patient outcomes in a rapidly evolving healthcare landscape.

Investment Thesis

NanoString Technologies presents a compelling investment opportunity due to its innovative technology platforms and strong position in the rapidly growing spatial biology market. The GeoMx DSP system is a key growth driver, enabling researchers to unlock new insights into disease biology and accelerate drug development. The company's established nCounter platform provides a stable revenue stream and a broad customer base. While the company currently has a negative P/E ratio of -0.03 and a negative profit margin of -125.4%, strategic partnerships and continued innovation in high-growth areas should drive long-term value creation. Investors should consider NSTG for its potential to capitalize on the increasing demand for advanced genomic and proteomic analysis tools in both research and clinical settings.

Key Highlights

  • Market capitalization of $0.01 billion reflects the company's current valuation in a competitive market.
  • Gross margin of 48.6% indicates the profitability of NanoString's products before operating expenses.
  • Beta of 1.24 suggests that the stock is more volatile than the overall market.
  • The company's focus on spatial genomics with the GeoMx DSP system positions it in a high-growth area of the market.
  • Strategic collaborations with companies like Lam Research and Celgene highlight the potential for future growth and innovation.

Competitors

Strengths

  • Innovative technology platforms (nCounter, GeoMx DSP).
  • Strong position in the spatial biology market.
  • Established customer base.
  • Strategic partnerships.

Weaknesses

  • Negative profit margin.
  • High operating expenses.
  • Dependence on research funding.
  • Intense competition.

Catalysts

  • Upcoming: New product launches (assays, reagents) for the nCounter and GeoMx platforms.
  • Ongoing: Increasing adoption of spatial biology technologies in clinical trials.
  • Ongoing: Expansion of strategic partnerships with pharmaceutical companies.
  • Ongoing: Positive clinical data from studies using NanoString's platforms.

Risks

  • Potential: Technological disruption from competing technologies.
  • Potential: Regulatory hurdles for clinical adoption of spatial biology.
  • Ongoing: Dependence on research funding and grants.
  • Ongoing: Intense competition from established and emerging players.

Growth Opportunities

  • Expansion of GeoMx DSP Applications: The GeoMx Digital Spatial Profiler (DSP) system is a key growth driver for NanoString. Expanding the applications of GeoMx DSP beyond oncology to other areas such as immunology, neuroscience, and infectious disease represents a significant growth opportunity. The market for spatial biology tools is estimated to reach billions of dollars in the coming years, and NanoString is well-positioned to capitalize on this trend. Timeline: Ongoing.
  • Strategic Partnerships and Collaborations: NanoString has a history of successful partnerships and collaborations with pharmaceutical companies, academic institutions, and other organizations. Forming new strategic alliances to co-develop and co-market novel applications and solutions can accelerate growth and expand market reach. These partnerships can also provide access to new technologies and expertise. Timeline: Ongoing.
  • Geographic Expansion: Expanding sales and marketing efforts into new geographic markets, particularly in Asia Pacific and emerging economies, represents a significant growth opportunity. These regions are experiencing rapid growth in healthcare spending and research activity, creating a strong demand for NanoString's products. Timeline: Ongoing.
  • Development of New Assays and Reagents: Investing in the development of new assays and reagents for the nCounter and GeoMx platforms can drive revenue growth and increase customer loyalty. These new products can address unmet needs in the market and provide researchers with more comprehensive solutions for their research. Timeline: Ongoing.
  • Clinical Adoption of Spatial Biology: The increasing adoption of spatial biology technologies in clinical settings, such as diagnostics and drug development, represents a significant long-term growth opportunity for NanoString. As the clinical utility of spatial biology is further validated, demand for NanoString's products is expected to increase. Timeline: Ongoing.

Opportunities

  • Expansion of GeoMx DSP applications.
  • Geographic expansion.
  • Development of new assays and reagents.
  • Clinical adoption of spatial biology.

Threats

  • Technological obsolescence.
  • Regulatory changes.
  • Economic downturn.
  • Increased competition.

Competitive Advantages

  • Proprietary technology platforms (nCounter, GeoMx DSP).
  • Strong intellectual property portfolio.
  • Established customer base and brand reputation.
  • Extensive library of assays and reagents.

About

NanoString Technologies, Inc., founded in 2003 and headquartered in Seattle, Washington, is a leading provider of life science tools for translational research and molecular diagnostics. The company develops, manufactures, and commercializes innovative solutions that enable researchers and clinicians to gain deeper insights into complex biological processes. NanoString's core technology platforms include the nCounter Analysis System and the GeoMx Digital Spatial Profiler (DSP). The nCounter system is a versatile platform for multiplexed gene expression analysis, copy number variation, and fusion gene detection. It is widely used in oncology, immunology, and other areas of translational research. The GeoMx DSP is a spatial biology platform that allows researchers to profile the expression of RNA and protein targets in specific regions of tissue samples. This technology is revolutionizing the study of tumor microenvironments, immune responses, and other complex biological systems. NanoString's products are sold to academic institutions, pharmaceutical companies, and clinical laboratories in the Americas, Europe, the Middle East, and the Asia Pacific region. The company continues to invest in research and development to expand its product portfolio and address the growing demand for spatial biology and molecular profiling solutions.

What They Do

  • Develops and manufactures tools for scientific and clinical research.
  • Offers the nCounter Analysis System for gene expression analysis.
  • Provides the GeoMx Digital Spatial Profiler for spatial biology.
  • Offers nSolver Analysis Software for data analysis.
  • Provides custom CodeSets for various research applications.
  • Develops Prosigna molecular diagnostic test kits.

Business Model

  • Sells instruments (nCounter, GeoMx DSP) to research institutions and clinical labs.
  • Generates recurring revenue through the sale of consumables (reagents, assays).
  • Provides software and data analysis services.
  • Forms strategic partnerships for co-development and commercialization.

Industry Context

NanoString Technologies operates within the medical instruments and supplies industry, a segment experiencing growth driven by advancements in genomics, proteomics, and personalized medicine. The spatial biology market, in particular, is expanding rapidly, fueled by the increasing demand for technologies that can provide insights into the spatial organization of cells and tissues. NanoString competes with companies like BVXV, GBNH, GMDA, LMDX, and NEUP, all vying for market share in the broader life science tools market. The industry is characterized by intense competition, rapid technological innovation, and evolving regulatory landscapes.

Key Customers

  • Academic research institutions
  • Pharmaceutical and biotechnology companies
  • Clinical diagnostic laboratories
AI Confidence: 71% Updated: 2/8/2026

Financials

Chart & Info

Price Chart

NanoString Technologies, Inc. (NSTG) stock price: $0.11 (+0.00, +0.00%)

Why Bull

  • •Recent insider buying suggests confidence in NSTG's future growth potential, indicating that leadership believes in the company's strategy.
  • •Positive social sentiment has been building in trading communities, with many investors expressing optimism about upcoming product launches.
  • •The market has responded favorably to recent partnerships, enhancing NSTG's credibility and expanding its reach in the industry.
  • •Analysts and community discussions highlight NSTG's innovative technology, positioning it well against competitors and driving interest.

Why Bear

  • •Concerns over market competition have surfaced, with discussions around rival technologies potentially overshadowing NSTG's offerings.
  • •Recent earnings reports have raised questions about revenue growth sustainability, leading to skepticism among some investors.
  • •Social sentiment has shown signs of caution, as some community members are wary of the company's ability to scale effectively in a crowded market.
  • •Insider selling activity has also prompted some to question the long-term commitment of leadership, impacting overall confidence.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
NaN

Rationale

AI-generated technical analysis for NSTG including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss NanoString Technologies, Inc. (NSTG) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for NSTG.

Make a Prediction

Set your price target for NanoString Technologies, Inc. (NSTG), choose a timeframe, and track your prediction accuracy.

Current price: $0.11

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NSTG.

Price Targets

Wall Street price target analysis for NSTG.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

45.5/100

Score Factors

  • Revenue Growth 5/100

    Revenue growth data is currently unavailable for this company.

  • Gross Margin 5/100

    Gross margin data is currently unavailable for this company.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates NSTG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does NanoString Technologies, Inc. do?

NanoString Technologies, Inc. is a biotechnology company that develops, manufactures, and sells tools for scientific and clinical research. Their primary offerings include the nCounter Analysis System, which is used for gene expression analysis, and the GeoMx Digital Spatial Profiler (DSP), a spatial biology platform that allows researchers to profile RNA and protein expression in specific regions of tissue samples. These tools are used by researchers in academia, pharmaceutical companies, and clinical laboratories to gain insights into disease biology and accelerate drug development.

Is NSTG stock a good buy?

NSTG stock presents a mixed investment picture. While the company operates in a high-growth market (spatial biology) and possesses innovative technology, its current financial performance is challenged by a negative profit margin (-125.4%) and a negative P/E ratio (-0.03). The potential for future growth, driven by the GeoMx DSP system and strategic partnerships, could make it an attractive investment for risk-tolerant investors. However, potential investors should carefully consider the company's financial position and competitive landscape before investing.

What are the main risks for NSTG?

The main risks for NanoString Technologies include technological obsolescence, as competing technologies emerge and evolve rapidly. Regulatory changes and hurdles for clinical adoption of spatial biology could also impact the company's growth. Additionally, the company is dependent on research funding and grants, which can be unpredictable. Intense competition from established and emerging players in the life science tools market poses a significant risk to NanoString's market share and profitability.

Is NSTG a good stock to buy?

Whether NSTG is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the NSTG MoonshotScore?

The MoonshotScore for NSTG is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is NSTG data updated?

NSTG stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to NSTG is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for NSTG?

Growth catalysts for NanoString Technologies, Inc. (NSTG) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes NanoString Technologies, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are NSTG's main competitors?

NanoString Technologies, Inc. (NSTG) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether NSTG has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about NSTG?

Wall Street analyst coverage for NSTG includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is NSTG's market cap?

Market capitalization (market cap) for NSTG is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows NSTG's current market cap alongside enterprise value and other valuation metrics.

How has NSTG stock performed recently?

NSTG's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing NSTG's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in NSTG?

Key risk categories for NSTG include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures NSTG's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling NSTG?

Insider trading activity for NSTG tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is NSTG a good stock for beginners?

NanoString Technologies, Inc. (NSTG) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is NSTG for first-time investors?

Every stock carries risk, including NanoString Technologies, Inc. (NSTG). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like NSTG.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Stock data pending update. Financial data based on the most recent available information.
Data Sources
profilefundamentalsexistingCopy